Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial

Trial Profile

Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Ciclosporin; Ciclosporin; Fludarabine; Mycophenolate mofetil
  • Indications Acute myeloid leukaemia; Anaplastic large cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Graft-versus-host disease; Hairy cell leukaemia; Hodgkin's disease; Lymphomatoid granulomatosis; Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Sezary syndrome; Testicular cancer; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 19 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 12 Oct 2010 Planned end date changed from 1 Mar 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top